Literature DB >> 22766573

A case of severe staphylococcal septicaemia: septic arthritis and a mediastinal abscess following leflunamide therapy for rheumatoid arthritis.

Anjali Balasanthiran1, Tannaz Vakilgilani, Ken Darzy, Jeremy Axon.   

Abstract

This highly unusual case illustrates how a potentially life-threatening complication may develop insidiously in the context of immunosuppression. A 46-year-old woman presented with increasing malaise and a marked inflammatory response in the context of immunosuppressive therapy for rhueumatoid arthritis. On the basis of microbiological findings, the patient was treated for systemic staphylococcal infection with a prolonged antibiotic course. In addition, incision and drainage procedures were performed on associated, non-resolving abscesses at various sites. One particular lesion in the breast was slow to heal and was monitored with ultrasound imaging. Subsequent cross-sectional imaging revealed that this was, in fact, a large mediastinal abscess, eroding the manubrium and lying within close proximity of the aorta. The patient was eventually referred to a cardiothoracic unit for complete evacuation of this lesion. Following a prolonged illness and treatment period, the patient recovered well and successfully resumed employment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22766573      PMCID: PMC3029350          DOI: 10.1136/bcr.07.2009.2082

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  23 in total

Review 1.  Leflunomide: a review of its use in active rheumatoid arthritis.

Authors:  A Prakash; B Jarvis
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Severe infections following leflunomide therapy for rheumatoid arthritis.

Authors:  R Grover; V Dhir; R Aneja; V Arya; A Galle; V Marwaha; A Kumar
Journal:  Rheumatology (Oxford)       Date:  2006-05-22       Impact factor: 7.580

3.  [Tendon ruptures in rheumatic patients].

Authors:  A Wanivenhaus
Journal:  Z Rheumatol       Date:  2007-02       Impact factor: 1.372

Review 4.  Diagnosis and management of Staphylococcus aureus bacteraemia.

Authors:  D H Mitchell; B P Howden
Journal:  Intern Med J       Date:  2005-12       Impact factor: 2.048

5.  Staphylococcal post-sternotomy mediastinitis: five year audit.

Authors:  Arlo Upton; Sally A Roberts; Paget Milsom; Arthur J Morris
Journal:  ANZ J Surg       Date:  2005-04       Impact factor: 1.872

6.  Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.

Authors:  S Cohen; G W Cannon; M Schiff; A Weaver; R Fox; N Olsen; D Furst; J Sharp; L Moreland; J Caldwell; J Kaine; V Strand
Journal:  Arthritis Rheum       Date:  2001-09

7.  Manubrio-sternal joint sepsis in rheumatoid arthritis.

Authors:  G D Wright; L L Yoon; S D Roberts; R J Lee
Journal:  Postgrad Med J       Date:  1995-07       Impact factor: 2.401

8.  Oral carriage of staphylococci in patients with rheumatoid arthritis.

Authors:  M S Jackson; J Bagg; M N Gupta; R D Sturrock
Journal:  Rheumatology (Oxford)       Date:  1999-06       Impact factor: 7.580

Review 9.  Comorbidities in rheumatoid arthritis.

Authors:  Kaleb Michaud; Frederick Wolfe
Journal:  Best Pract Res Clin Rheumatol       Date:  2007-10       Impact factor: 4.098

10.  Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study.

Authors:  V Mladenovic; Z Domljan; B Rozman; I Jajic; D Mihajlovic; J Dordevic; M Popovic; M Dimitrijevic; M Zivkovic; G Campion
Journal:  Arthritis Rheum       Date:  1995-11
View more
  1 in total

1.  Brain abscess in a rheumatoid arthritis patient treated with leflunomide - A case presentation and review.

Authors:  Efthymia Samara; Ioannis Siasios; Konstantinos Katsiardanis; Eirini Liaptsi; Kalliopi Tsoleka; Georgia Deretzi
Journal:  Surg Neurol Int       Date:  2021-03-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.